TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11932115

Group type: EXPERIMENTAL
Intervention: Tailored communications
Number of subjects: 213

Group type: COMPARATOR
Intervention: Generic communications
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Tailored communications with physician discussion
Number of subjects: 213

Group type: COMPARATOR
Intervention: Generic communications with physician discussion
Number of subjects: 213
Study: 10525755

Group type: EXPERIMENTAL
Intervention: Venlafaxine 18.75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8544292

Group type: EXPERIMENTAL
Intervention: Lancet point type
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pencil point type
Number of subjects: 30
Study: 1771173

Group type: EXPERIMENTAL
Intervention: Aspartame (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose (100 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 8
Study: 7067996

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-administered, mailed questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 0
Study: 31693974

Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: BD patients
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combination of IL-6, IL-8, ST2, sTNFR2, IL-12, and TNF-α
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: MDD patients with melancholic features
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: sTNFR1 / sTNFR2 ratio
Number of subjects: 304
Study: 31375128

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant juice (BJ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched placebo (PLA)
Number of subjects: 40
Study: 28736045

Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine
Number of subjects: 92269

Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine
Number of subjects: 92269
Study: 24937346

Group type: EXPERIMENTAL
Intervention: Provider hands as a reservoir of Enterococcus
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Possible intraoperative bacterial transmission events
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Confirmed transmission events
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Phenotypes E5 and E7
Number of subjects: 389
Study: 24629994

Group type: EXPERIMENTAL
Intervention: Monovalent human-bovine rotavirus vaccine (116E)
Number of subjects: 6799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study: 23059783

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Erlotinib and Placebo
Number of subjects: 441
Study: 19702643

Group type: EXPERIMENTAL
Intervention: Total Therapy 3 (TT3) with added bortezomib
Number of subjects: 441

Group type: COMPARATOR
Intervention: Total Therapy 2 (TT2)
Number of subjects: 441
Study: 18090468

Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal bearings
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metal-on-metal bearings
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ceramic-on-ceramic bearings
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene bearings
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Laboratory studies
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adverse conditions with rim loading
Number of subjects: 31
Study: 15151172

Group type: EXPERIMENTAL
Intervention: TMZ MR 35 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMZ IR 20 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMZ MR in dogs and pigs (multiple dose simulations)
Number of subjects: 0
Study: 11579646

Group type: EXPERIMENTAL
Intervention: Ketanserin gel (2%)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Clioquinol cream and/or Lassar paste
Number of subjects: 66
Study: 9675961

Group type: EXPERIMENTAL
Intervention: Pr IR 150 mg x 3
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pr SR 325 mg x 2
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pr SR 225 mg x 2
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 8017357

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, twice daily for 2 months)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2872793

Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (5 to 30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 to 80 mg)
Number of subjects: 18
Study: 31889507

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Clinical scores (Centor and FeverPAIN)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 169
Study: 29572695

Group type: EXPERIMENTAL
Intervention: Swim-up method
Number of subjects: 65
Study: 27546364

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 72 hours after symptoms
Number of subjects: 62

Group type: COMPARATOR
Intervention: Delayed cholecystectomy after 6-8 weeks (control group)
Number of subjects: 62
Study: 24848492

Group type: COMPARATOR
Intervention: FR+inactive (low physical activity, approximately 4500 steps per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FR+active (high physical activity, approximately 12,500 steps per day)
Number of subjects: 22
Study: 22588154

Group type: EXPERIMENTAL
Intervention: CT screening with five annual low-dose CT scans
Number of subjects: 4104

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 4104
Study: 20718170

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18572758

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 31-gauge needle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gas-powered, needle-free injection device (NFID)
Number of subjects: 60
Study: 18569233

Group type: EXPERIMENTAL
Intervention: Oxitropium (200 microg by MDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg by Handihaler)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ipratropium (40 microg by MDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Comparison of PD(15)FEV(1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dose-response slope
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Correlation between PD(15)FEV(1) and FEV(1)% increase
Number of subjects: 44
Study: 15519014

Group type: EXPERIMENTAL
Intervention: Carvedilol (initiated before ACEI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: ACEI (initiated after carvedilol)
Number of subjects: 78
Study: 10783403

Group type: EXPERIMENTAL
Intervention: Atomized 4% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 40
Study: 9084344

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day with intensive language therapy for 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo with intensive language therapy for 6 weeks
Number of subjects: 66
Study: 8251285

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1, 0.2, 0.4, or 1 mg kg‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.005, 0.01, 0.02, or 0.05 mg kg‐1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Spontaneous recovery (Control)
Number of subjects: 64
Study: 3711547

Group type: EXPERIMENTAL
Intervention: Exercise-induced asthma with endogenous adrenergic activity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerosol of norepinephrine during exercise-induced asthma
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocapnic hyperventilation (control)
Number of subjects: 10
Study: 31256599

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplementation (3000 mg daily in 3 doses)
Number of subjects: 54
Study: 30029523

Group type: EXPERIMENTAL
Intervention: High-dose 'Benifuuki' extract (676 mg of catechins)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Low-dose 'Benifuuki' extract (322 mg of catechins)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No 'Benifuuki' extract (control group)
Number of subjects: 159
Study: 27472361

Group type: EXPERIMENTAL
Intervention: Casein protein (CAS, 120 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-nutritive placebo (PLA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Casein protein (CAS)
Number of subjects: 12
Study: 24213961

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS (Control)
Number of subjects: 40
Study: 22404221

Group type: EXPERIMENTAL
Intervention: Swallowing exercise (placing a milk bolus of 0.05‐0.2 mL on the tongue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucking exercise (active sucking on a pacifier)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 19445637

Group type: EXPERIMENTAL
Intervention: Portable media consoles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Television-based consoles
Number of subjects: 0
Study: 17218570

Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive mechanical ventilation (NIMV) for 3 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham NIMV for 3 months
Number of subjects: 23
Study: 15482044

Group type: EXPERIMENTAL
Intervention: ABCT with interventions encouraging Alcoholics Anonymous (AA) involvement (AA/ABCT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ABCT with relapse prevention techniques (RP/ABCT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alcohol behavioral couples therapy (ABCT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatments (ABCT, RP/ABCT, AA/ABCT)
Number of subjects: 90
Study: 21236721

Group type: EXPERIMENTAL
Intervention: High-dose/short-term hepatitis B vaccination schedules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New immunogenic formulations of hepatitis B vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early vaccination of potential transplant candidates
Number of subjects: 0
Study: 9596305

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day for 3 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg twice a day for 3 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol (both dosages)
Number of subjects: 16
Study: 7829764

Group type: EXPERIMENTAL
Intervention: TRH tests administered before, during, and after ECT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Initial TSH response to TRH
Number of subjects: 31
Study: 3122559

Group type: EXPERIMENTAL
Intervention: Early initiation of enteral nutrition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study: 28833808

Group type: EXPERIMENTAL
Intervention: Trenonacog alfa (IB1001)
Number of subjects: 76
Study: 27278935

Group type: EXPERIMENTAL
Intervention: Cash and in-kind food transfer programme
Number of subjects: 0
Study: 26051569

Group type: EXPERIMENTAL
Intervention: Acupressure backrest for 1 month
Number of subjects: 64

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preferred acupressure backrest for 1 month
Number of subjects: 64
Study: 23018904

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 20459634

Group type: EXPERIMENTAL
Intervention: Physical activity and dietary pattern interventions
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 1500
Study: 18403102

Group type: EXPERIMENTAL
Intervention: Irrigation with ISO 0.1 microg/mL
Number of subjects: 12

Group type: COMPARATOR
Intervention: Irrigation with saline
Number of subjects: 12
Study: 16788315

Group type: EXPERIMENTAL
Intervention: rFVIIa (40 microg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard haemostatic replacement therapy (placebo)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 76
Study: 12135219

Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 21
Study: 9925060

Group type: EXPERIMENTAL
Intervention: 3 mg/d of beclomethasone dipropionate (BDP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7572574

Group type: COMPARATOR
Intervention: rTPA alone (100 mg in 3 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rTPA plus nitroglycerin (100 micrograms/min)
Number of subjects: 60
Study: 2180474

Group type: EXPERIMENTAL
Intervention: Early treatment with oxprenolol or oxprenolol plus dihydralazine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group with matching placebos
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Early treatment with oxprenolol
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 7000303

Group type: EXPERIMENTAL
Intervention: Bacampicillin 1.6g with probenecid 1g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin 3.5g with probenecid 1g
Number of subjects: 0
Study: 30225529

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 41
Study: 28358815

Group type: EXPERIMENTAL
Intervention: Azathioprine 50mg for 24, 36 or 48 weeks with steroid treatment (oral prednisolone for 20 weeks)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Steroid treatment (oral prednisolone for 20 weeks)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Azathioprine treatment for 48 weeks
Number of subjects: 279

Group type: COMPARATOR
Intervention: Steroid treatment
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Azathioprine and Dapsone together
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combined treatment with steroids and azathioprine
Number of subjects: 279
Study: 25981347

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF) at doses of 5.3 mg and 10.7 mg total CF/kg body weight (BW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acetaminophen (1 g) as control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF)
Number of subjects: 40
Study: 23321963

Group type: EXPERIMENTAL
Intervention: email
Number of subjects: 20180

Group type: EXPERIMENTAL
Intervention: letter
Number of subjects: 20180

Group type: COMPARATOR
Intervention: reports
Number of subjects: 20180

Group type: EXPERIMENTAL
Intervention: email (patients <18 years)
Number of subjects: 20180

Group type: EXPERIMENTAL
Intervention: letter (patients ≥18 years)
Number of subjects: 20180

Group type: COMPARATOR
Intervention: patient-reported assessments
Number of subjects: 20180
Study: 21415263

Group type: EXPERIMENTAL
Intervention: Supervised treadmill training for 12 weeks at home, exercising twice a week at an intensity of 66% of HR(peak)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study: 19548433

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Estazolam (Control)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Both TCM and Estazolam
Number of subjects: 336
Study: 18021477

Group type: EXPERIMENTAL
Intervention: Taxanes added to anthracycline-based schedule (either concomitantly or sequentially)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Taxanes in both treatment arms
Number of subjects: 9
Study: 15285157

Group type: EXPERIMENTAL
Intervention: PET (Positron Emission Tomography)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET combined with CT
Number of subjects: 0
Study: 11384639

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone started on the day of oocyte retrieval (group A, n = 43)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Vaginal progesterone started on the evening of ET (group B, n = 41)
Number of subjects: 84
Study: 9279224

Group type: EXPERIMENTAL
Intervention: T-tube system
Number of subjects: 484

Group type: COMPARATOR
Intervention: Pressure support ventilation of 7 cm H2O
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Reintubated patients
Number of subjects: 484

Group type: COMPARATOR
Intervention: Successfully extubated patients
Number of subjects: 484
Study: 8346490

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formoterol 6 micrograms
Number of subjects: 15
Study: 3016080

Group type: EXPERIMENTAL
Intervention: Topical human fibroblast interferon
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31516094

Group type: EXPERIMENTAL
Intervention: Probiotics + sertraline (PS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sertraline alone (S)
Number of subjects: 48
Study: 31806719

Group type: EXPERIMENTAL
Intervention: Individualised treatment targeting treatable traits
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study: 30197271

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition at 3 hours post-PEG placement (group 1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Delayed enteral nutrition at 8 hours post-PEG placement (group 2)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 28763875

Group type: EXPERIMENTAL
Intervention: Nattokinase (NK) at a daily dose of 6000 FU for 26 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Statin (simvastatin 20 mg) daily for 26 weeks
Number of subjects: 82
Study: 26268133

Group type: EXPERIMENTAL
Intervention: 2h abbreviated fasting with oral ingestion of a carbohydrate and protein solution
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional fasting
Number of subjects: 38
Study: 24072755

Group type: EXPERIMENTAL
Intervention: Decision aid plus usual care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 80
Study: 21732797

Group type: EXPERIMENTAL
Intervention: Insulin bolus-patch
Number of subjects: 38
Study: 20146874

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol and remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volatile induction and maintenance of anaesthesia (VIMA) with sevoflurane
Number of subjects: 40
Study: 16980833

Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM) intervention to increase use of HPDs
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1245
Study: 15151689

Group type: EXPERIMENTAL
Intervention: PRO-SELF: Candidiasis intervention program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intervention group (PRO-SELF: Candidiasis)
Number of subjects: 35
Study: 10868638

Group type: EXPERIMENTAL
Intervention: Quadruple induction therapy (tacrolimus, azathioprine, ALG Merieux, and prednisolone)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dual induction therapy (tacrolimus and prednisolone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quadruple induction therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dual induction therapy
Number of subjects: 120
Study: 9171470

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Environmental air (placebo)
Number of subjects: 14
Study: 8218538

Group type: EXPERIMENTAL
Intervention: rhIL-3 (0.25, 1.0, 2.5, 5.0, and 10.0 micrograms/kg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhIL-3 (10 micrograms/kg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhIL-3 (highest dose levels)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhIL-3
Number of subjects: 21
Study: 3957502

Group type: EXPERIMENTAL
Intervention: Flunarizine 20 mg/per os/day for 14 days, followed by 10 mg/per os/day up to 120 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 30
Study: 2454374

Group type: EXPERIMENTAL
Intervention: Carvedilol i.v. (15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Labetalol i.v. (40 mg and 80 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 24
Study: 31554874

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (group A with 13 cases)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgery (group B with 16 cases)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgery (group B)
Number of subjects: 29
Study: 28170094

Group type: EXPERIMENTAL
Intervention: Freeze-dried amnion graft
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 88
Study: 25738668

Group type: EXPERIMENTAL
Intervention: Goserelin with standard chemotherapy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 257
Study: 23385648

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg, titrated to 10 mg)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Atenolol (50 mg, titrated to 100 mg)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Comparison of bisoprolol and atenolol
Number of subjects: 209
Study: 21561817

Group type: EXPERIMENTAL
Intervention: Mindfulness-based (MB) ME
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nonjudgmental (NJ) ME
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based (CD) ME
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 168